Vascular Endothelial Growth Factor A clinical trials
Counted the way a researcher would: Vascular Endothelial Growth Factor A with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses Vascular Endothelial Growth Factor A is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Other names
- VEGF
- 1
Studies by the year they started
3 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 1
Shanghai Henlius Biotech (2) · Losordo, Douglas, M.D. (1)
Studies
Open first, then newest update. How each study uses Vascular Endothelial Growth Factor A is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMDCompletedPhase 3Shanghai Henlius BiotechNCT05003245Written as HLX04-O,recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injectionHow we know
- Evaluate the Safety and Efficacy of HLX04-O in Subjects With wAMDCompletedPhase 1/2Shanghai Henlius BiotechNCT04993352Written as recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injectionHow we know
- VEGF Gene Transfer for Diabetic NeuropathyCompletedPhase 1/2Losordo, Douglas, M.D.NCT00056290Written as VEGFHow we know